AR081535A1 - Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso - Google Patents

Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso

Info

Publication number
AR081535A1
AR081535A1 ARP110101298A ARP110101298A AR081535A1 AR 081535 A1 AR081535 A1 AR 081535A1 AR P110101298 A ARP110101298 A AR P110101298A AR P110101298 A ARP110101298 A AR P110101298A AR 081535 A1 AR081535 A1 AR 081535A1
Authority
AR
Argentina
Prior art keywords
patients
agent
ready
stable
combinations
Prior art date
Application number
ARP110101298A
Other languages
English (en)
Inventor
Sigal First
Original Assignee
Cts Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cts Chemical Ind Ltd filed Critical Cts Chemical Ind Ltd
Publication of AR081535A1 publication Critical patent/AR081535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una formulación líquida oleosa estable lista para usar caracterizada porque comprende (i) un ingrediente farmacéutico activo que tiene propiedades hidrofóbicas y/o lipofílicas y/o que presenta problemas de estabilidad en ambientes acuosos, (ii) un vehículo oleoso en el cual se disuelve o se dispersa el ingrediente farmacéutico activo, que se selecciona entre los aceites vegetales, los aceites sintéticos y los ácidos grasos, o combinaciones de éstos; y opcionalmente uno o más componentes seleccionados entre un agente espesante/de suspensión, un antioxidante, con conservante, un agente floculante, un agente de estabilización superficial, un edulcorante, un agente saborizante, un emulsionante y un agente colorante, o combinaciones de éstos.Reivindicación 17: La formulación líquida oleosa estable lista para usar de acuerdo con cualquiera de las reivindicaciones 1 a 15, caracterizada porque puede usarse para el tratamiento médico de grupos de pacientes seleccionados entre (i) los pacientes pediátricos, (ii) los pacientes de la tercera edad, (iii) los pacientes que padecen disfagia o (iv) los pacientes que deben recibir su medicación por vía nasogástrica o a través de sondas gastrostómicas.
ARP110101298A 2010-04-16 2011-04-14 Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso AR081535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010015143A DE102010015143A1 (de) 2010-04-16 2010-04-16 Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon

Publications (1)

Publication Number Publication Date
AR081535A1 true AR081535A1 (es) 2012-10-03

Family

ID=44628325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101298A AR081535A1 (es) 2010-04-16 2011-04-14 Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso

Country Status (9)

Country Link
US (1) US20130115294A1 (es)
EP (2) EP2558071A2 (es)
AR (1) AR081535A1 (es)
AU (1) AU2011241896B2 (es)
CA (1) CA2796581A1 (es)
DE (1) DE102010015143A1 (es)
IL (1) IL218113A0 (es)
TW (1) TW201210634A (es)
WO (1) WO2011128783A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877259B2 (en) 2012-02-09 2014-11-04 Mary Kay Inc. Cosmetic formulation
EP2874624B8 (en) 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
US8568747B1 (en) * 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
GB201306720D0 (en) * 2013-04-12 2013-05-29 Special Products Ltd Formulation
EP3253211A4 (en) * 2015-02-05 2018-10-31 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
CN113197851A (zh) * 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
EP3500309A1 (en) * 2016-08-17 2019-06-26 Rosemont Pharmaceuticals Limited Stable atorvastatin suspension composition
EP3299017A1 (en) * 2016-09-23 2018-03-28 The Boots Company PLC Formulation
GB201804621D0 (en) 2018-03-22 2018-05-09 Bcm Specials Ltd Formulation
SG11202103284QA (en) * 2018-10-25 2021-05-28 Cindome Pharma Inc Formulations containing deuterated domperidone
CN111840227B (zh) * 2020-08-31 2022-02-22 陕西九州制药有限责任公司 氨酚曲马多口服乳液及其制备方法
CN113952298B (zh) * 2021-12-08 2023-02-17 江苏农牧科技职业学院 硫酸头孢喹肟纳米混悬液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889709A (en) * 1985-03-18 1989-12-26 Product Resources International, Inc. Aerosol foam with adsorbate and container containing same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
CA2392353A1 (en) * 1999-11-22 2001-05-31 Galephar Pharmaceutical Research, Inc. Stable acid labile benzimidazole pharmaceutical compositions
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
EP1663173A1 (en) * 2003-09-25 2006-06-07 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20060024335A1 (en) * 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
EP1957085A2 (en) * 2005-11-08 2008-08-20 Ranbaxy Laboratories, Ltd. Macrolides as anti-inflammatory agents
FR2914188B1 (fr) * 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one

Also Published As

Publication number Publication date
WO2011128783A2 (en) 2011-10-20
AU2011241896B2 (en) 2013-09-26
DE102010015143A1 (de) 2011-10-20
AU2011241896A1 (en) 2012-11-22
WO2011128783A3 (en) 2012-04-19
TW201210634A (en) 2012-03-16
US20130115294A1 (en) 2013-05-09
EP2558071A2 (en) 2013-02-20
IL218113A0 (en) 2012-04-30
EP2674152A1 (en) 2013-12-18
CA2796581A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
AR081535A1 (es) Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
BR112014010275A2 (pt) formulações para tratamento de diabetes
BR112016018673A2 (pt) Composições de sistemas de distribuição de nanoemulsão
CO2018003424A2 (es) Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
AR059829A1 (es) Sistemas estables de nanocapsulas para la administracion de moleculas activas
CL2022002084A1 (es) Formulaciones farmacéuticas
CL2013003365A1 (es) Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros.
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE20130045A1 (es) FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
PE20120584A1 (es) Preparaciones farmaceuticas transdermicas
AR060784A1 (es) Mezclas binarias de acido hialuronico y su uso terapeutico
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
BR112022012216A2 (pt) Formulação de cuidado de saúde sólida, formulação líquida para cuidado de saúde, e emulsão para cuidados de saúde
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
AR077490A1 (es) Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel

Legal Events

Date Code Title Description
FB Suspension of granting procedure